Larson Financial Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Larson Financial Group's NBIX Position: Q3 2026 in Review
Larson Financial Group increased its Neurocrine Biosciences (NBIX) stake by 149% in Q3 2026, buying an estimated $367K and bringing the position to 3,817 shares worth $541K. The position accounts for 0.01% of the portfolio, ranked #564.
Larson Financial Group first reported a position in NBIX in Q2 2022 and has held it in 16 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Larson Financial Group held 3,817 shares of Neurocrine Biosciences worth $541K as of Q3 2026.
- Larson Financial Group bought 2,281 Neurocrine Biosciences shares in Q3 2026, an estimated $367K.
- Neurocrine Biosciences made up 0.01% of Larson Financial Group's portfolio in Q3 2026, its #564 holding.
- Larson Financial Group first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 16 quarters since.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.